Romero GA

Language: Spanish
References: 11
Page:
PDF size: 284.34 Kb.

Text Extraction

No abstract.

REFERENCES

1. Li Q, Lin XJ, Chen H, Gong J, Li Z, Chen ZN. Co-existence of isodicentric Ph chromosomes and the three-way Ph chromosome variant t(3;9;22)(p21;q34;q11) in a rare case of chronic myeloid leukemia. Oncol Lett. 2018;15(4):4599-603. doi: 10.3892/ol.2018.7866

2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. CA Cancer J Clin. 2020;70:7-30.

3. Welch HG, Kramer BS, Black WC. Epidemiologic signatures in cancer. N Engl J Med. 2019;381:1378-86.

4. Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. Hematol Am Soc Hematol Educ Program. 2019;433-42.

5. American Cancer Society: Cancer Facts and Figures 2019. Atlanta, Ga: American Cancer Society; 2019.

6. American Cancer Society. Terapias dirigidas para la leucemia mieloide crónica. American Cancer Society. 2018 (acceso: 08/08/2019) Disponible en: Disponible en: https://www.cancer.org/es/cancer/leucemia-mieloide-cronica/tratamiento/terapias-dirigidas.html

7. Apperley J, Niederwieser D, Huang XJ, Nagler A, Fuchs E, Szer J et al. Haploidentical hematopoietic stem cell transplantation: A global overview comparing Asia, the European Union, and the United States. Biol Blood Marrow Transplant. 2016;22(1):23-6.

8. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-84. doi:10.1038/s41375-020-0776-2

9. Annunziata M, Bonifacio M, Breccia M, Castagnetti F, Gozzini A, Iurlo A, et al. Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia. Front Oncol. 2020;10:883. doi:10.3389/fonc.2020.00883

10. Rabian F, Lengline E, Rea D. Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia. Curr Hematol Malig Rep. 2019;14(6):492-500. doi:10.1007/s11899-019-00546-4

11. Yamamoto C, Nakashima H, Ikeda T, Kawaguchi SI, Toda Y, Ito S, et al. Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation. Blood Adv. 2019;3:3266-77.